A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis

W. Hader, P. Duquette, A. Auty Winnipeg, S. Hashimoto, J. Noseworthy, G. Sawa, D. Brunet, R. Nelson, T. Gray, G. Klein, G. Francis, Y. Lapierre, B. Weinshenker, W. Barkas, S. Philips, M. Girard, T. J. Murray

Research output: Contribution to journalArticlepeer-review

126 Scopus citations


One hundred and fifteen patients with definite multiple sclerosis (M.S.) and chronic persistent fatigue were studied. This ten-week cross-over study consisted of a 2-week baseline period and two 3-week treatment periods separated by a 2-week washout. Patients received either amantadine 100 mg bid or matching placebo capsules. Fatigue, the effect of fatigue on an individually pre-selected activity and its effect on activities of daily living, were evaluated. Amantadine produced a small but statistically significant decrease in fatigue. An important placebo effect was noted. Mean fatigue during the washout period was lower than during the placebo run-in period, independently of which treatment had been given first. Side effects were numerous both on amantadine and on placebo. Only insomnia was significantly more common with amantadine.

Original languageEnglish (US)
Pages (from-to)273-278
Number of pages6
JournalCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Issue number3
StatePublished - Aug 1987

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis'. Together they form a unique fingerprint.

Cite this